Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified

References

• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.
   PubMed Web of Science ®Google Scholar
• Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021.
   Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357.
   PubMed Web of Science ®Google Scholar
• Jones NR, McCormack T, Constanti M, et al. Diagnosis and management of hypertension in adults: NICE guideline update 2019. Br J Gen Pract. 2020;70(691):90–91.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. For the INVEST investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–2816.
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5(5):561–572.
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension. 1991;17(4):579–588.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751–1756.
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J. 1985;291:97–104.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs–overview and meta-analyses. J Hypertens. 2015;33(2):195–211.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, et al. For the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J. 2008;336:1121–1123.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Bazoukis G, Tsioufis C, et al. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020;38(9):1669–1681.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, et al. For the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–598.
   PubMed Web of Science ®Google Scholar
• Mancia G, Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens. 2008;26(2):164–168.
   PubMed Web of Science ®Google Scholar
• Riemer TG, Villagomez Fuentes LE, Algharably EAE, et al. Do β-blockers cause depression? Systematic review and meta-analysis of psychiatric adverse events during β-blocker therapy. Hypertension. 2021;77(5):1539–1548.
   PubMed Web of Science ®Google Scholar
• Farmakis IT, Pyrgidis N, Doundoulakis I, et al. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. Cardiovasc Drugs Ther. 2021:1–12.
   PubMed Web of Science ®Google Scholar
• Espinola-Klein C, Weisser G, Jagodzinski A, et al. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58(2):148–154.
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Xiang Z-J, Yang J-H, et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41(46):4415–4422.
   PubMed Web of Science ®Google Scholar
• Grassi G, Quarti-Trevano F, Seravalle G, et al. Association between the European Society of Cardiology/European Society of Hypertension heart rate thresholds for cardiovascular risk and neuroadrenergic markers. Hypertension. 2020;76(2):577–582.
   PubMed Web of Science ®Google Scholar
• Esler M, Lambert G, Esler D, et al. Evaluation of heart rate as a sympathetic nervous system biomarker in essential hypertension. J Hypertens. 2020;38(8):1488–1495.
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988;259(13):1976–1982.
   PubMed Web of Science ®Google Scholar
• Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens. 1991;4(2 Pt 1):151–158.
   PubMed Web of Science ®Google Scholar
• The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens. 1985;3:379–392.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Eide I, Leren P, et al. The effect on HDL cholesterol of oxprenolol and atenolol. Scand J Clin Lab Invest. 1982;42(5):449–453.
   PubMed Web of Science ®Google Scholar
• Grassi G, Mancia G, Esler M. Central and peripheral sympathetic activation in heart failure. Cardiovasc Res. 2022;118(2):1857–1871.
   PubMedGoogle Scholar
• Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26(5):1257–1263.
   PubMed Web of Science ®Google Scholar
• Frishman WH. β-adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013;18(4):310–319.
   PubMed Web of Science ®Google Scholar
• do Vale GT, Ceron CS, Gonzaga NA, et al. Three generations of β-blockers: class differences and clinical applicability. Curr Hypertens Rev. 2019;15(1):22–31.
   PubMed Web of Science ®Google Scholar
• Vanhoutte PM, Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol. 2013;13(2):265–273.
   PubMed Web of Science ®Google Scholar
• Pucci G, Ranalli MG, Battista F, et al. Effects of β-blockers with and without vasodilating properties on central blood pressure. Systematic review and meta-analysis of randomized trials in hypertension. Hypertension. 2016;67(2):316–324.
   PubMed Web of Science ®Google Scholar
• Kreutz R. Algharably EAe-H. In: Offermanns S, and Rosenthal W eds. Encyclopedia of molecular pharmacology. Cham: Springer International Publishing; 2021. p. 165–174.
   Google Scholar
• Seleme VB, Marques GL, Mendes AEM, et al. Nebivolol for the treatment of essential systemic arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021;21(2):165–180.
   PubMed Web of Science ®Google Scholar
• Kostis JB, DeFelice EA, Frishman W, et al. Clinical relevance of intrinsic sympathomimetic activity of beta-blockers. Angiology. 1981;32(11):780–787.
   PubMed Web of Science ®Google Scholar
• Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(Suppl 3):S13–S16.
   PubMedGoogle Scholar
• Schnabel P, Maack C, Mies F, et al. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J Cardiovasc Pharmacol. 2000;36(4):466–471.
   PubMed Web of Science ®Google Scholar
• McEniery CM, Cockcroft JR, Roman RJ, et al. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35(26):1719–1725.
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225.
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804–1814.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817–821.
   PubMed Web of Science ®Google Scholar
• Kapoor JR, Heidenreich PA. Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Heart Failure. 2010;16(10):806–811.
   Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
   PubMed Web of Science ®Google Scholar
• Chan You S, Krumholz HM, Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line β-blocker monotherapy in hypertensive patients: a large-scale multicenter observational study. Hypertension. 2021;77(5):1528–1538.
   PubMed Web of Science ®Google Scholar
• Thomsen ARB, Plouffe B, Cahill TJ, et al. GPCR-G protein-β-arrestin super-complex mediates sustained G protein signaling. Cell. 2016;166(4):907–919.
   PubMed Web of Science ®Google Scholar
• Wang J, Hanada K, Staus DP, et al. Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling. Nat Commun. 2017;8(1):1706.
   PubMedGoogle Scholar
• Kim IM, Tilley DG, Chen J, et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA. 2008;105(38):14555–14560.
   PubMed Web of Science ®Google Scholar
• Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA. 2007;104(42):16657–16662.
   PubMed Web of Science ®Google Scholar
• Esler M, Jennings G, Korner P, et al. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11(1):3–20.
   PubMed Web of Science ®Google Scholar
• Anderson EA, Sinkey CA, Lawton WJ, et al. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1989;14(2):177–183.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Miyajima E, Tochikubo O, et al. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989;13(6 Pt 2):870–877.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic nervous augmentation in essential hypertension: role of nerve firing, norepinephrine reuptake and angiotensin neuromodulation. Hypertension. 2004;43(2):169–175.
   PubMed Web of Science ®Google Scholar
• Grassi G, Colombo M, Seravalle G, et al. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31(1):64–67.
   PubMed Web of Science ®Google Scholar
• Grassi G, Dell’Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with the metabolic syndrome. Diabetologia. 2005;48(7):1359–1365.
   PubMed Web of Science ®Google Scholar
• Esler M, Lambert E, Schlaich M. Point: counterpoint. Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol. 2010;109(6):1996–1998.
   PubMed Web of Science ®Google Scholar
• DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245–R253.
   PubMed Web of Science ®Google Scholar
• Esler M, Lambert G, Schlaich M, et al. Obesity paradox in hypertension. Is this because sympathetic activation in obesity-hypertension takes a benign form? Hypertension. 2018;71(1):22–33.
   PubMed Web of Science ®Google Scholar
• Esler M. Sympathetic activation in essential hypertension: understanding the toxic trifecta. Heart Lung Circ. 2018;27(3):271–273.
   PubMed Web of Science ®Google Scholar
• Radaelli A, Mircoli L, Mori I, et al. Nitric oxide-dependent vasodilation in young spontaneously hypertensive rats. Hypertension. 1998;32(4):735–739.
   PubMed Web of Science ®Google Scholar
• Kaplon RE, Walker AE, Seals DR. Plasma norepinephrine is an independent predictor of vascular endothelial function with aging in healthy women. J Appl Physiol. 2011;111(5):1416–1421.
   PubMed Web of Science ®Google Scholar
• Sverrisdottir YB, Jansson LM, Hagg U, et al. Muscle sympathetic nerve activity is related to a surrogate marker of endothelial function in healthy individuals. PLOS One. 2010;5(2):e9257.
   PubMed Web of Science ®Google Scholar
• Topal E, Cikim AS, Cikim K, et al. The effect of moxonidine on endothelial function in metabolic syndrome. Am J Cardiovasc Drugs. 2006;6:343–348.
   PubMedGoogle Scholar
• Lichtor T, Davis HR, Johns L, et al. The sympathetic nervous system and atherosclerosis. J Neurosurg. 1987;67(6):906–914.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108(5):560–565.
   PubMed Web of Science ®Google Scholar
• Esler M. Mental stress and human cardiovascular disease. Neurosci Biobehav Rev. 2017;74(Pt B):269–276.
   PubMedGoogle Scholar
• Shivkumar K, Ajijola OA, Anand I, et al. Clinical neurocardiology – defining the value of neuroscience-based cardiovascular therapeutics. J Physiol. 2016;594(14):3911–3954.
   PubMed Web of Science ®Google Scholar
• Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010;31(18):2271–2279.
   PubMed Web of Science ®Google Scholar
• Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109(5):685–692.
   PubMed Web of Science ®Google Scholar
• Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971;44(3):413–418.
   PubMed Web of Science ®Google Scholar
• Mancia G, Masi S, Palatini P, et al. Elevated heart rate and cardiovascular risk in hypertension. J Hypertens. 2021;39(6):1060–1069.
   PubMed Web of Science ®Google Scholar
• Mancia G, Kjeldsen SE, Kreutz R, et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 ESC/ESH Hypertension Guidelines. Hypertension. 2022;79(6):1153–1166.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Vaduganathan M, Claggett BL, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction. DELIVER trial. JACC Heart Fail. 2022;10(3):184–197.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, von Lueder TG, Smiseth OA, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension. 2020;75(1):23–32.
   PubMed Web of Science ®Google Scholar